Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04659668
Other study ID # MD/MMG-23-04-2019
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 11, 2019
Est. completion date August 17, 2020

Study information

Verified date December 2020
Source Mesoestetic Pharma Group S.L.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is an open-label uncontrolled single-center study for the evaluation of the Performance characteristics (efficacy and safety) of the dermal filler "MMG-23-04-2019" on the female genital area for the medicinal, functional and reconstructive indications.


Description:

The Dermal Filler is recommended for the female intimate areas, especially the internal area of the vagina (vaginal vestibule, introitus, vaginal walls, clitoris, "G" spot) for the following indications: vaginal dryness or discomfort, vaginal atrophy. The main functional ingredient is cross-linked hyaluronic acid of non-animal origin, produced through bacterial fermentation. The MMG-23-04-2019 is contained in pre-filled, graduated and disposable sterile syringe with Luer Lock adapter with 1 ml of net content and 20 mg/ml hyaluronic acid. The MMG-23-04-2019 has been classified as a Class III medical device under Annex IX of Directive MDD 93/42 EEC since it is a long-term, invasive and absorbable medical device.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date August 17, 2020
Est. primary completion date June 12, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Female subject aged =18; - Subject presenting vaginal atrophy, dryness, dyspareunia or discomfort in the intimate area; - Subject who presents no other type of pathology of the area to be treated; - Subject who is willing to abstain from any cosmetic or surgical procedures in the treatment area during the clinical investigation; - Subject who is willing to participate in all study related activities and who is available for the duration of their participation in the investigation for follow-up; - Absence of a history of significant hypersensitivity to food and drugs or known sensitivity to hyaluronic acid; - Clinically and anamnestic healthy individual; - Arterial blood pressure (BP) (after 5 min. at rest in the supine position) systolic 90 - 140 mmHg and diastolic 50 - 90 mmHg; - Heart rate (HR) (after 5 min. at rest in the supine position) over 50 beats/min and less than 90 beats/min; - Respiratory rate between 12 - 24 breaths/min; - An axillar body temperature of up to 37 degrees celsius; - Clinical-laboratory examinations within the reference ranges or with no clinically significant abnormalities; - Negative AIDS/HIV test; - Negative pregnancy test for the women with reproductive potential; - A reliable and acceptable method of contraception for the women of child-bearing potential: - Signed written Informed Consent Form Exclusion Criteria: - Subject with known sensitivity to hyaluronic acid or significant hypersensitivity to food and drugs; - Subject with a history of vulvar cancer and/or previous regional radiotherapy; - Subject with genital prolapse with a surgical indication or stress incontinence with a surgical indication; - A subject who suffers from vaginism; - Subject with genital bleeding of unknown origin; - Subject with frequent or present active herpes simplex or herpes zoster local infection or active herpes simplex or herpes zoster infection in other sites; - Subject with a history of frequent or active local dermatitis (of the injection site), vulvar scaly papilloma, mycosis; bacterial infection or laboratory tests indicating for such; - A subject suffering from autoimmune diseases or who are undergoing treatment with immunosuppressors or immunotherapy; - Subject with uncontrolled systemic diseases or who are undergoing current treatment with antihypertensives, steroid anti-inflammatory drugs anticoagulants, aspirin, major antidepressants; - Pregnancy, postpartum period (6 months), lactation or post-lactation period (6 months); - Absence of a reliable and effective method of contraception for a subject with childbearing potential; - Subjects who are currently receiving another investigational treatment or who had participated in another clinical investigation within 30 days prior to study enrollment; - A subject who suffer from another medical condition or who are receiving medication that in the Principal Investigator's judgment would prohibit the inclusion in the study; - Subject with limited mental activity and consistent comprehension ability; sportsmen and individuals on strenuous physical loading; prisoners; - Refusal to sign the Informed Consent Form.

Study Design


Intervention

Device:
MMG-23-04-2019
The dermal filler MMG-23-04-2019 is applied to the female intimate area (intramucosal administration) of vaginal vestibule, vaginal walls, clitoris, "G" spot.

Locations

Country Name City State
Bulgaria Medical Centre Ramus Sofia

Sponsors (1)

Lead Sponsor Collaborator
Mesoestetic Pharma Group S.L.

Country where clinical trial is conducted

Bulgaria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Vaginal Maturation Index (VMI) absolute change Improvement in the properties of the vaginal wall, measured by the VMI. From baseline to Day 60 (up to 8 weeks).
Primary Treatment-Emergent Adverse Events [Safety and Tolerability] Frequency and severity of adverse events (AEs) and adverse device effect From screening through study completion, an average of 60 days - daily.
Secondary The change in the Gloria Bachmann Vaginal Health Index (VHI) The VHI is a score formed by 5 parameters (vaginal elasticity, vaginal secretions, pH, epithelial mucous membrane, vaginal hydration). The final score defines the degree of atrophy in the genitourinary tract by assigning a single score to each parameter. The maximum possible score is 25, while the minimum possible score is 5. From baseline to Day 30 (4 weeks) and Day 60 (up to 8 weeks).
Secondary The absolute change in Visual Analogous Scale (VAS). The absolute change in VAS, ranged between 0 (no pain) and 10 (worst possible pain), judged by the Principal Investigator. From baseline to Day 30 (4 weeks) and Day 60 (up to 8 weeks).
Secondary The absolute change in Visual Analogous Scale (VAS) The absolute change in VAS ranged between 0 (no pain) and 10 (worst possible pain), judged by the subject. From Day 0 to Day 30 (4 weeks) and Day 60 (up to 8 weeks).
Secondary The change of the Female Sexual Function Index (FSFI) score. The FSFI is a validated questionnaire to measure the sexual functioning of women. The score ranges between 2 (minimum) and 36 (maximum). From Day 0 to Day 30 and Day 60 (up to 4 weeks and 8 weeks respectively).
Secondary Subject satisfaction evaluated by the Global Impression of Improvement (PGI-I) questionnaire The PGI-I is a transition single question scale, asking the patient to rate their urinary tract condition now, as compared with how it was prior to before beginning treatment on a scale from 1 (Very much better) to 7 (Very much worse) From Day 30 (4 weeks) to Day 60 (up to 8 weeks).
Secondary The change if the Nugent Score The Nugent Score is a Gram stain scoring system for vaginal swabs to diagnose bacterial vaginosis, relying on scoring of individual types of organisms; a score of 0 to 10 is derived from a weighted combination of the following: large Gram-positive rods (lactobacilli; decrease in Lactobacillus scored as 0 to 4), small Gram-negative or Gram-variable rods (G. vaginalis or other anaerobes; scored as 0 to 4), and curved Gram-negative or Gram-variable rods (Mobiluncus spp.; scored as 0 to 2). From baseline to Day 60 (up to 8 weeks).
Secondary Viganal biopsy (optional) Evaluation of the mitotic activity of the mucosa (Ki-67 proliferation marker - %). From Day 0 up to Day 60 (up to 8 weeks).
Secondary Participant's Questionnaire To register the overall discomfort and satisfaction of the subjects. From Day 0 to Day 30 and Day 60 (up to week 4 and 8 respectively).
See also
  Status Clinical Trial Phase
Recruiting NCT05534412 - A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence N/A
Recruiting NCT05515198 - Improving Care for Women With Urinary Incontinence (EMPOWER) N/A
Completed NCT04071301 - Collection of Real-life Measurement Data for TENA SmartCare Change Indicator in Subjects With Urinary Incontinence N/A
Completed NCT03623880 - Enhancing Behavioral Treatment for Women With Pelvic Floor Disorders N/A
Recruiting NCT05880862 - Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls Early Phase 1
Recruiting NCT04159467 - Effect of Pelvic Floor Muscle Training on Urinary Incontinence Reports in Obese Women Undergoing a Low Calorie Diet N/A
Completed NCT05485922 - Performance of a Single-use Intermittent Micro-hole Zone Catheter N/A
Completed NCT06268782 - The Effectiveness of an Online Exercise Program on Well-being of Postpartum Women N/A
Not yet recruiting NCT03027986 - Evaluation of a Postural Rehabilitation Program Based on Sensory-motor Control in Men With Urinary Incontinence After Prostatectomy N/A
Recruiting NCT02490917 - ACT™ Balloons Versus Artificial Urinary Sphincter (AMS800™) for the Treatment of Female Stress Urinary Incontinence N/A
Enrolling by invitation NCT02529371 - Pre-Marketing Feasibility Evaluation of the UriCap-RM - Urine Collection in Hospitalized Male Patients N/A
Enrolling by invitation NCT02530372 - Feasibility of the UriCap-F for Urine Collection in Hospitalized Women N/A
Completed NCT02600676 - Transcutaneous Electric Nerve Stimulation (TENS) in Children With Enuresis N/A
Completed NCT02549729 - Effect of the Pelvic Floor Training in Postmenopausal Women With or Without Hormonal Therapy N/A
Completed NCT02338726 - Pelvic Floor Symptoms and Quality of Life in Elderly Women - a Population-based Pilot Study N/A
Completed NCT02368262 - Prevalence of Incontinence and Risk Factors in Children With Cerebral Palsy N/A
Completed NCT02239796 - Feasibility Controlled Trial of Tibial Nerve Stimulation for Stroke Related Urinary Incontinence N/A
Completed NCT01942681 - Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride N/A
Recruiting NCT01804153 - Stem Cells Tratment for the Local Feminine Stress Urinary Incontinence Treatment (HULPURO) Phase 1/Phase 2
Completed NCT01520948 - Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease Phase 3